Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV

dc.contributor.author
Duart Castells, Leticia
dc.contributor.author
López Arnau, Raúl
dc.contributor.author
Buenrostro Jáuregui, Mario
dc.contributor.author
Muñoz-Villegas, P.
dc.contributor.author
Valverde, Olga
dc.contributor.author
Camarasa García, Jordi
dc.contributor.author
Pubill Sánchez, David
dc.contributor.author
Escubedo Rafa, Elena
dc.date.issued
2020-01-20T12:19:53Z
dc.date.issued
2020-01-20T12:19:53Z
dc.date.issued
2018-10-12
dc.date.issued
2020-01-20T12:19:53Z
dc.identifier
0028-3908
dc.identifier
https://hdl.handle.net/2445/148191
dc.identifier
682923
dc.description.abstract
3,4-methylenedioxypyrovalerone (MDPV) is a synthetic cathinone with cocaine-like properties. In a previous work, we exposed adolescent mice to MDPV, finding sensitization to cocaine effects, and a higher vulnerability to cocaine abuse in adulthood. Here we sought to determine if such MDPV schedule induces additional behavioral-neuronal changes that could explain such results. After MDPV treatment (1.5 mg·kg-1, twice daily, 7 days), mice were behaviorally tested. Also, we investigated protein changes in various brain regions MDPV induced aggressiveness and anxiety, but also contributed to a faster habituation to the open field. This feature co-occurred with an induction of ΔFosB in the orbitofrontal cortex that was higher than its expression in the ventral striatum. Early after treatment, D2R:D1R ratio pointed to a preponderance of D1R but, upon withdrawal, the ratio recovered. Increased expression of Arc, CDK5 and TH, and decrease in DAT protein levels persisted longer after withdrawal, pointing to a neuroplastic lasting effect similar to that involved in cocaine addiction. The implication of the hyperdopaminergic condition in the MDPV-induced aggressiveness cannot be ruled out. We also found an initial oxidative effect of MDPV, without glial activation. Moreover, although initially the dopaminergic signal induced by MDPV resulted in increased ΔFosB, we did not observe any change in NFκB or GluA2 expression. Finally, the changes observed after MDPV treatment could not be explained according to the autoregulatory loop between ΔFosB and the epigenetic repressor G9a described for cocaine. This provides new knowledge about the neuroadaptive changes involved in the vulnerability to psychostimulant addiction.
dc.format
11 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Elsevier Ltd
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1016/j.neuropharm.2018.10.005
dc.relation
Neuropharmacology, 2018, vol. 144, p. 271-281
dc.relation
https://doi.org/10.1016/j.neuropharm.2018.10.005
dc.rights
cc-by-nc-nd (c) Elsevier Ltd, 2018
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject
Cocaïna
dc.subject
Dopamina
dc.subject
Amfetamines
dc.subject
Ratolins
dc.subject
Drogues de disseny
dc.subject
Cocaine
dc.subject
Dopamine
dc.subject
Amphetamines
dc.subject
Mice
dc.subject
Designer drugs
dc.title
Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)